I reread the announcement, there is a lot more to it if you read it carefully.
It sort of says Lion and PYC are the only shareholders(by implication) and that PYC has 51% worst case.
"PYC can increase its shareholding in Vision in return for providing funding for the progression of Vision Pharma’s programs through IND-enabling and, subsequently, clinical studies."
I read this as "if" PYC had money then it could use it to fund these programs in Vision, making the finished product more "ours" through the increased shareholding. So it sounds as if the only other shareholder is Lion, but maybe Sue has a small amount as she is a key player we have now added to our firepower. So if someone wanted into PYC with a chunk of cash PYC could use it to push vision, or not. Or PYC could raise thru the various mechanisms to push Vision if it looked the goods.
Given they will be inventing then trialling many aso's not just this one, i feel a lot more news will come out of this collaboration over then next 12 months, If we can get a third party to license the platform as well things will take a serious step forward. The conference in germany might awaken many others to the success that is apparent here.
Frequent mention of " for which there is no effective treatment" means we will definitely not have much competition and may mean we can apply for that pediatric USA voucher.... worth a cool hundred million (or more) if we sold our option. A billion US dollars in sales annually for the first disease they crack( Ret Pigmentosa), perhaps less for others, that's a serious carrot to dangle.
PYC Price at posting:
4.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)